Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: 3D Medicines, Alphamab, Apollomics, Eisai, Eli Lilly, Innovation, Lupin, Moderna, Roche, Shionogi, Samsung Bioepis, Sorrento, Tracon, Vasomune.
LONDON – Results from the phase I/II trial of Coronavac, a COVID-19 vaccine based on a traditional inactivated whole SARS-CoV-2 virus that circulated in China in the early days of the pandemic, show it is safe and induces an antibody response in healthy volunteers ages 18 to 59.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Agenus, Arch, Arcturus, Celltrion, Daewoong, Eisai, Humanigen, Immunitybio, Inmune, Israel Institute for Biological Research, Neurorx, Novartis, Pfizer, Relief, Sheba Medical Center.
Biopharmas in Asia-Pacific raising money in public or private financings, including: Fountain Healthcare Partners, Inmagene, Inotrem, Kyowa Kirin, Mainstay Medical Holdings, Memo, Patrys, Priothera, Vaxil Bio.
HONG KONG – Humanigen Inc. has executed its first licensing agreement in the Asia-Pacific region, in a deal worth up to $20 million that gives Telcon RF Pharmaceutical Inc. and KPM Tech Co. Ltd. the development and commercialization rights to lenzilumab for COVID-19 in South Korea and the Philippines.
RSS
